<DOC>
	<DOC>NCT02064634</DOC>
	<brief_summary>This study investigates how gastrointestinal toxicity affects discontinuation of medication given to patients with osteoarthritis in routine clinical practice.</brief_summary>
	<brief_title>A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Minimum 20 yearold patients diagnosed with osteoarthritis Within 2 weeks prior to participation, not taken antiinflammatory analgesic drug such as the Shinbaro Capsule, Celecoxib Capsule and NSAIDs(nonsteroidal antiinflammatory drugs) Written consent form voluntarity Diagnosed with disease that may affect measurement of efficacy clinically Diagnosed with clinically significant phycological disorder, and taking medication Participated in a clinical trial within 4 weeks Pregnant or lactating woman History of malignant disease within the previous 5 years Patients who seem not to participate in the study at investigator's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Shinbaro Capsule</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>GCSB-5</keyword>
	<keyword>Discontinuation rate</keyword>
	<keyword>Gastrointestinal adverse event</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>OASIS</keyword>
</DOC>